Pricing Log in Create free account

Lyell Immunopharma, Inc. (LYEL) vs ProQR Therapeutics N.V. (PRQR)

Lyell Immunopharma, Inc. and ProQR Therapeutics N.V. are both Biotechnology companies. Lyell Immunopharma, Inc. and ProQR Therapeutics N.V. are of similar size ($204.6M and $200.7M). ProQR Therapeutics N.V. grew revenue faster over the last twelve months: 19.7% against −55.0%. ProQR Therapeutics N.V. has the higher net margin (−228.7% vs −920,285.2%) and the higher return on invested capital (0.00% vs −539.5%). Across the 16 metrics below, ProQR Therapeutics N.V. leads on 10 and Lyell Immunopharma, Inc. on 6.

Valuation

Metric LYEL PRQR Biotechnology median
P/E n/m n/m 8.50
P/S 7,009.20 6.71 9.71
P/B 0.81 1.56 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.06 n/m 0.64
EV/Sales (550.13) 0.85 9.21
Earnings yield (158.40%) (35.11%) (33.15%)
Free cash flow yield (92.40%) (39.84%) (25.50%)

Profitability

Metric LYEL PRQR Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (949,981.48%) (233.33%) 0.00%
Net margin (920,285.19%) (228.71%) 0.00%
Free cash flow margin (647,681.48%) (267.36%) 0.00%
Return on equity (93.28%) (58.29%) (56.36%)
Return on assets (71.34%) (31.53%) (48.04%)
Return on invested capital (539.53%) 0.00% 0.00%

Growth

Metric LYEL PRQR Biotechnology median
Revenue growth (TTM) (55.00%) 19.72% 6.02%
EPS growth (last fiscal year) 38.70% (28.57%) 30.26%
Revenue growth, 5-year CAGR (65.85%) — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric LYEL PRQR Biotechnology median
Debt to equity 0.00 0.06 0.00
Current ratio 5.36 3.49 4.72
Net debt to EBITDA 0.94 2.15 0.96

Dividend

Metric LYEL PRQR Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric LYEL PRQR Biotechnology median
Market cap 200.70m 204.63m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack